Breaking News

Cryoport to Support ImmunoCellular’s Cold Chain Logistics

Phase III glioblastoma trial spans 120 sites in North America and Europe

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cryoport, Inc. will support the cryogenic logistics for ImmunoCellular Therapeutics’ Phase III glioblastoma trial across 120 sites in North America and Europe. This trial will evaluate the safety and efficacy of ImmunoCellular’s lead product candidate ICT-107, a patient-derived dendritic cell-based immunotherapy.   Anthony Gringeri, ImmunoCellular’s senior vice president, Strategic Resources, said, “We chose to partner with Cryoport for the registrational trial of ICT-107 because of their cold...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters